“我认为围绕生物技术划定界限并把整个行业称为关键行业不会达到目的,”罗森表示,“我们必须能够继续对投资具体情况具体分析。”
The promise of genomics is a new era of precision targeted drugs that make traditional one-size-fits-all medicine look like a second world war dumb bomb. But treatments that are customised for a patient’s individual genetic make-up remain in their early stages.
基因组研究有望带来精准靶向药物的新时代,这种药物使传统的通用药物看起来就像是二战时的傻瓜炸弹。但针对病人个人基因组的定制治疗方案仍然处于早期阶段。
Both the US, the acknowledged global leader, and China are pursuing personalised treatments for diseases such as cancer, cystic fibrosis or Alzheimer’s. China last year unveiled a $9bn 15-year research initiative, dwarfing an Obama-era plan that earmarked $215m for the National Institutes of Health.
美国(目前公认的全球领头羊)和中国都在积极研究癌症、囊性纤维化和阿尔茨海默症(Alzheimer's)等疾病的个人化治疗。去年中国公布了一项90亿美元的15年研究计划,令奥巴马时代为美国国家卫生研究院(NIH)拨款2.15亿美元的计划相形见绌。
DNA science has leapfrogged since 2000 when the human genome was first sequenced. What once required years of work and cost billions of dollars now takes less than a week and costs just $1,000. The US is gathering genetic data from more than 1m volunteers, so that automated lab systems can investigate how individual genes interact.
【大国角力的新领域:基因数据】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15